Table 4.
Participants who had at least one adverse event episode during the observed continuous KRT sessions
| Variables, n (%) | No-Anticoagulation Group (n=45) | Regional Citrate Anticoagulation Group (n=44) |
|---|---|---|
| Ca2+tot/Ca2+ion >2.5 | 3 (7) | 25 (57) |
| Ca2+tot/Ca2+ion >2.5a | 3 (11) | 20 (67) |
| Hypercalcemiab | 1 (2) | 3 (7) |
| Hypocalcemiac | 23 (51) | 36 (82) |
| Hypocalcemiaa,c | 15 (54) | 25 (83) |
| Severe hypocalcemiad | 6 (13) | 34 (77) |
| Severe hypocalcemiaa,d | 6 (21) | 24 (80) |
| Severe alkalosise | 4 (9) | 4 (9) |
| Metabolic acidosisf | 1 (2) | 4 (9) |
a
Sensitivity analysis included only the first filter of continuous KRT.
b
Systemic total calcium level >10.0 mg/dl.
c
Systemic ionized calcium level <4.0 mg/dl.
d
Systemic ionized calcium level <3.6 mg/dl.
e
pH >7.50 and bicarbonate concentration >30 mEq/L.
f
pH <7.20 and bicarbonate concentration <20 mEq/L.